the official website of the antibody society
For World Cancer Day 2024, The Antibody Society has prepared a snapshot of the clinical development of therapeutic antibodies for cancer indication.
The infographic gives an overview on the trends in first in human studies and approvals, as well as on the active early and late stage pipelines (as of January 2024).
The Antibody Society
Antibody Engineering & Therapeutics commences on Thursday, December 14, 2023! Visit us at Booth #113 for a free T shirt and networking.
And don’t miss the keynote address by Dr. Heather Bax, the 2023 Huston Award recipient.
Need insights into the early-stage antibody therapeutics pipeline? We’ve got you covered! Join us Tuesday Oct 24th for an in-depth analysis of the early-stage pipeline stratified by cancer and non-cancer indications, revealing trends in the molecular formats, targets, and mechanism of action.
Abstract: Since 2014, the number of antibody therapeutics entering clinical development annually has increased steadily, from 71 in 2014 to 286 in 2022. This has resulted in a clinical pipeline currently composed of ~1250 molecules, of which ~1100 and ~150 molecules are in early- and late-stage development, respectively. Despite the great interest in trends in early-stage clinical development, due to the difference in scale and difficulty in tracking molecules newly entered in clinical studies, analyses of trends in the global commercial development of antibody therapeutics are often limited to the late-stage clinical pipeline only. Luckily, The Antibody Society meticulously collects data for antibody therapeutics at all stages of clinical development. This webinar will provide an exhaustive analysis of the early-stage pipeline stratified by cancer and non-cancer indications, revealing trends in the molecular formats, targets, and mechanism of action.
Our student winner is:
Mr. Matheus Oliveira De Souza (Ragon institute of MGH, MIT and Harvard, MIT, The University of Kansas)
Poster title: Enhanced antibody recognition against HIV resistant strains by directed evolution
Our post-doc winner is:
Dr. Nayara Braga Emidio (National Institutes of Health (NIH))
Poster title: Generation of neurokinin receptor ligands with specialized signalling properties via nanobody conjugation
The Antibody Society sponsors competitions each year to recognize and encourage the research activities of promising student/postdoctoral fellows. For the Research Competition, participants submitted a summary of their work on a topic related to antibody research. Winners (1 student and 1 post-doc) were selected based on originality, creativity, scientific merit, clarity of their research and its presentation.
Winners will receive:
Information on past competitions and winners can be found here.
The Huston Award is given by The Antibody Society to recognize and encourage upcoming scientists in the field of antibody engineering and therapeutics. Early-career research scientists who have received an advanced degree (Ph.D., M.D., or equivalent) within the past 10 years are eligible for the Award. The scientist is recognized for making important contributions to the antibody field and/or the dissemination of antibody knowledge. The recipient will be invited to give a live webinar on their work, which will also be made available on demand on The Antibody Society’s Learning Center and YouTube channel, and to give a lecture at the Antibody Engineering & Therapeutics conference.
The Award includes:
The award criteria and application details are here. Please note: Applicants must be nominated by a Member of the The Antibody Society.
What is it like to win? Our 2022 Huston Award recipient, Prof. Brandon DeKosky, describes his experience in this 2-min video.
